ArticleResearch square2025
Oropouche virus disrupts neurodevelopment and is vertically transmitted.
Article in Research square, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Oropouche virus (OROV) historically caused a self-limiting disease, yet recent strains are associated with congenital infection and neurodevelopmental disruption. These cases highlight a need to study OROV as a congenital pathogen and determine the impact of infection on neurodevelopment. Here, we show that OROV is vertically transmitted and induces a microcephaly-like phenotype in human forebrain organoids. We found OROV robustly infects human neural progenitor cells in organoids. In contrast to ZIKV, OROV had a heightened capacity for infection and organoid pathology. We show this increased pathogenesis is partially attributable to OROV antagonism of innate immune signaling. We further demonstrate that OROV is vertically transmitted and infects the fetal tissues in a murine model of congenital infection. Our results demonstrate that OROV can be vertically transmitted and has heightened capacity for neurodevelopmental disruption. These findings underscore need for monitoring OROV as a re-emerging virus capable of inducing microcephaly in infected fetuses.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.